Zacks: Analysts Anticipate Qiagen NV (QGEN) to Announce $0.24 EPS

Wall Street analysts forecast that Qiagen NV (NASDAQ:QGEN) will post earnings of $0.24 per share for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Qiagen’s earnings. The lowest EPS estimate is $0.23 and the highest is $0.25. Qiagen posted earnings of $0.22 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 9.1%. The business is expected to issue its next quarterly earnings report on Tuesday, May 1st.

According to Zacks, analysts expect that Qiagen will report full-year earnings of $1.34 per share for the current year, with EPS estimates ranging from $1.32 to $1.38. For the next financial year, analysts expect that the business will report earnings of $1.52 per share, with EPS estimates ranging from $1.45 to $1.58. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that cover Qiagen.

A number of research analysts recently commented on QGEN shares. Zacks Investment Research lowered Qiagen from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. Cowen restated a “hold” rating and issued a $34.00 target price on shares of Qiagen in a research note on Thursday, December 21st. Deutsche Bank restated a “buy” rating on shares of Qiagen in a research note on Wednesday, November 8th. DZ Bank restated a “neutral” rating on shares of Qiagen in a research note on Tuesday, December 19th. Finally, TheStreet upgraded Qiagen from a “c+” rating to a “b+” rating in a research note on Tuesday, November 7th. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Qiagen presently has a consensus rating of “Hold” and an average price target of $35.33.

Shares of Qiagen (QGEN) traded up $0.80 during midday trading on Friday, hitting $31.81. The company had a trading volume of 1,429,788 shares, compared to its average volume of 1,440,000. The company has a quick ratio of 4.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $7,340.00, a price-to-earnings ratio of 81.56, a price-to-earnings-growth ratio of 1.98 and a beta of 1.03. Qiagen has a twelve month low of $27.74 and a twelve month high of $36.34.

Qiagen declared that its board has initiated a stock repurchase program on Wednesday, January 31st that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.

Institutional investors have recently added to or reduced their stakes in the business. American International Group Inc. acquired a new position in Qiagen during the fourth quarter worth $154,000. Lourd Capital LLC acquired a new stake in Qiagen in the 4th quarter valued at approximately $223,000. Hartford Investment Management Co. acquired a new stake in Qiagen in the 3rd quarter valued at approximately $231,000. Trexquant Investment LP acquired a new position in shares of Qiagen during the 3rd quarter worth approximately $234,000. Finally, Prudential Financial Inc. increased its position in shares of Qiagen by 9.8% during the 2nd quarter. Prudential Financial Inc. now owns 7,841 shares of the company’s stock worth $263,000 after purchasing an additional 700 shares during the last quarter. Hedge funds and other institutional investors own 62.49% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at

About Qiagen

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Get a free copy of the Zacks research report on Qiagen (QGEN)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with's FREE daily email newsletter.

Leave a Reply